Lykos Could See Five-Year Delay In Possible FDA Approval Of MDMA

After FDA’s recent rejection of Lykos Therapeutics’ application for midomafetamine (MDMA) for post-traumatic stress disorder (PTSD), the company and other developers hoping to for the first time treat mental health conditions with MDMA could see a five-year delay before any of their products potentially reach patients in the United States. “I think we're going to see at least a five-year delay for MDMA in the U.S.,” Sam Clark, CEO of Terran Biosciences, told Inside Health Policy. “The issue is...